摘要
目的观察还原型谷胱甘肽对帕金森病人临床疗效及安全性。方法选择77例帕金森病病人,随机分为对照组38例、治疗组39例,两组均常规抗PD治疗,而治疗组联用谷胱甘肽,连续4周,治疗前后行血SOD、GSH-Px、MDA测定;治疗组、对照组进行治疗前后H-Y分级及帕金森病统一评分量表的第二分量表(UPDRSII)评定临床疗效。结果GSH治疗后,SOD、GSH-Px值较治疗前明显升高(P<0.05、P<0.01),MDA值下降(P<0.05),而对照组改变不明显。治疗前后UPDRSII评分及H-Y分级有明显改善(P<0.05、P<0.01),与对照组比较,疗后UPDRSII评分两组有显著差异(P<0.05)。结论在短期临床观察中GSH对PD病人有较显著的治疗作用。
Objective To investigate the clinical and safety efficacy of reduced glutathione(GSH) on patients of Parkinson's disease.Methods 77 clinical cases were divided into two groups:GSH treatment group(38 cases) subject to intravenous injection of GSH 600mg combined with anti-Parkinsoian therapy;and control group(39 cases) subject to anti-Parkinsoian therapy only.Their blood superoxide dismutase(SOD), glutathione peroxidase(GSH-Px) and malodialdehyde(MDA) were determined before and after 4 weeks' treatment. The clinical efficacy were assessed with Hoehn Yahr grading and the United Parkinson's Disease Rating Scale II part (UPDRS II) score between the two groups.Results After the GSH treatment,the GSH group's SOD,GSH-Px were clearly higher than before(P<0.05,P<0.01) while their MDA dropped(P<0.05).The control group did not show obvious changes.The H-Y grading and UPDRS II scores revealed that after the treatment the clinical signs in the GSH group were noticeably improved(P<0.05?P<0.01).In comparison with the control group,there was a clear difference of UPDRS II scores (P<0.05).Conclusion GSH has a noticeable efficacy on patients of Parkinson's disease in short-term clinical observison.
出处
《中国实用医药》
2006年第3期13-15,共3页
China Practical Medicine
关键词
还原型谷胱甘肽
帕金森病
氧化应激
reduced glutathione
Parkinson's disease
oxidative stress
